Market comparison
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
1 venue · 1 outcome rows · 0 comparable lines · 0 verified parity · active
Kalshi
Open venue ↗1 outcomes · $9K reported volume
Observed 3m ago
Recorded venue end date: Jan 1, 2027
Check settlement rules before comparing contracts. Matched outcomes may settle differently. These are stored prices; record update times do not certify live quotes. Differences exclude fees and available size.
No shared outcome identities or comparable outcome lines are available for this event. Each venue’s outcomes are listed separately.
| Outcome | Kalshi | Difference |
|---|---|---|
a full approval or an accelerated approval Not alignedNo persisted outcome identity connects these venue contracts. | — |
a full approval or an accelerated approval
Not alignedNo persisted outcome identity connects these venue contracts.
Kalshi
Prices are shown as percentages of a $1 payout. “pp” means percentage points. A dash means data is unavailable.